Evidence map›Paper›PMID 29411131›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2018

Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients.

John Hilton, Lisa Vandermeer, Marta Sienkiewicz, Sasha Mazzarello, Brian Hutton, Carol Stober, Dean Fergusson, Phillip Blanchette, Anil A Joy, A Brianne Bota and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

John HiltonDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada. jfhilton@toh.ca.
Lisa VandermeerOttawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.
Marta SienkiewiczOttawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.
Sasha MazzarelloOttawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.
Brian HuttonOttawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.
Carol StoberOttawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.
Dean FergussonOttawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.
Phillip BlanchetteDepartment of Oncology, Division of Medical Oncology, London Regional Cancer Program, University of Western Ontario, London, Canada.
Anil A JoyDepartment of Oncology, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada.
A Brianne BotaOttawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.
Mark ClemonsDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada.ORCID http://orcid.org/0000-0002-0738-2713
University of Ottawa · CAUniversity of Alberta · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDespite its widespread use as primary febrile neutropenia (FN) prophylaxis during chemotherapy for early-stage breast cancer, the optimal duration of daily filgrastim is unknown. Using the minimum effective duration may improve patient comfort and acceptability while reducing costs. Yet, suboptimal dosing may also negatively impact patient care. A survey was performed to obtain information regarding current practices for granulocyte colony-stimulating factor (G-CSF) use.

methodsCanadian oncologists involved in the treatment of breast cancer patients, as well as patients who had received neo/adjuvant chemotherapy for breast cancer, were surveyed. Standardized surveys were designed to collect information on perceived reasons for G-CSF use and current practices.

resultsThe surveys were completed by 38/50 (76%) physicians and 95/97 (98%) patients. For physicians, there was variability in the choice of chemotherapy regimens that required G-CSF support, the dose of filgrastim prescribed and the number of days prescribed. The majority of physicians reported using 5 (31.6%), 7 (47.4%), or 10 (13.2%) days of therapy. Nearly half of the patients (46.3%) recalled having experienced at least one of the chemotherapy-related complications including chemotherapy delays, dose reductions, and FN. While on filgrastim, 66.3% of patients reported myalgia and bone pain. Both physicians and patients expressed interest in participating in clinical trials designed to optimize the duration of filgrastim administration.

conclusionsSignificant variability in practice exists with respect to filgrastim administration. Definitive studies are therefore required to standardize and improve care, as this has the potential to impact treatment outcomes, patient quality of life, and cost savings.

Indexed as

AdultAgedBreast NeoplasmsFemaleFilgrastimHematologic AgentsHumansMiddle AgedNeoplasm StagingPatientsPhysiciansSurveys and QuestionnairesTreatment OutcomeYoung AdultFilgrastimHematologic AgentsChemotherapyFilgrastimG-CSF support

Identifiers

PMID29411131
OpenAlexW2794179848

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.